Home
Why EFUDEX®?
Indications
How EFUDEX® Works
Treatment
FAQ / What to Expect
Other Products
Links
References
For Additional Information Call:
United States 1.800.556.1937
1. Data on file, Valeant Pharmaceuticals International.
2.Lober BA, Lober CW. Actinic keratosis in squamous cell carcinoma. South Med J 2000;93:650-655.
3. American Cancer Society, Inc. Detailed Guide: Skin Cancer Nonmelanoma: what is nonmelanoma skin cancer? Available at: http://www.cancer.org/. Accessed February 19, 2004.
4. Miller DL, Weinstock, MA. Nonmelanoma Skin Cancer in the United States. J AM Acad Derm. 1994;30(5):774-778.
5. IMS Audit Data, month ending February 2005.
6. Tanghetti E. Comparison of 5-Fluorouracil 5% Cream and Imiquimod 5% Cream for actinic keratoses. Presented at: 29th Hawaii Dermatology Seminar; March 18-24 2005; Wailea, Maui, Hawaii.
7. Tanghetti EA. Comparison of 5-Fluorouracil 5% and Imiquimod 5% for actinic keratoses. Cos Derm. 2004;17(suppl 3):16-20.
8. Jeffes EWB, Chen JT. New approaches to the treatment of actnic keratosis. Am J Cancer. 2003;2:115-168.
9. Stein L. Sun damage, moles, and skin cancer [Medscape Web site]. Available at: http://www.medscape.com/viewprogram/249_pnt. Accessed April 7, 2005.
10. Abel EA, Bercovitch LG, Stoll HL. When actinic keratoses are a problem. Patient Care. 1992;26:115-133.
11. Wrone DA. 5-Fluorouracil versus suergery in superficial basal cell carcinoma and other skin malignancies. Cos Derm. 2004;17(suppl 3):7-10.
12. Leffell DJ, Cerucci JA. Management of skin cancer. In: DeVita VT, Hellman S. Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott, Williams and Wilkins; 2001:1976-2202.
13. IMS Audit Data, ending March 2005.
14. Maddin S. Dermatologic therapy. In: Moschella SL, Hurley HJ, eds. Dermatology. 2nd ed. Philadelphia , PA : WB Saunders Co; 1985:1946-1979.
15. Simmonds WL. Management of actinic keratoses with topical 5-fluorouracil. Cutis. 1976;18:298-300.
16. Strum HM, Scott H. Treatment of actinic keratosis with topical 5-fluorouracil. J Med Assoc Ga . 1968;(suppl 7): 205-209.
17. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil mechanism of action in human skin and actinic keratosis. I. Effect on DNA synthesis in vivo. Arch Dermatol . 1970;101(2):132-139
18. Belisario JC. Topical cytotoxic therapy of solar keratoses with 5-fluorouracil. Med J Aust . 1969;2(23):1136-1140.
19. Arnold JL, Odom RB, James WD. Andrews' Diseases of the Skin. 8th ed. Philadelphia , PA : WB Saunders Company; 1990:756.
20. Willis I. Photosensitivity and phototherapy. In: Moschella SL, Hurley HJ, eds. Dermatology . 2nd ed. Philadelphia , PA : WB Saunders Company; 1985:389-424.
21. Kircik L. Efficacy of 5% F-Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma. Presented at: 29th Hawaii Dermatology Seminar; March 18-24 2005; Wailea, Maui, Hawaii.
Printer Friendly
Prescribing Information
  • Over 14 million prescriptions have been written for Efudex over last 30 years5
  • High success rates
IMPORTANT SAFETY INFORMATION
EFUDEX® (fluorouracil) Topical Solutions and Cream is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established.
EFUDEX is contraindicated in women who are, or may become, pregnant during therapy because of potential hazards to the fetus. Cases of miscarriage and birth defects have been reported in women who are pregnant.
The most frequent adverse events occur locally and may include itching, burning, soreness, tenderness, scaling, and swelling. Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration.
Please see complete Prescribing Information for EFUDEX.
© Valeant Pharmaceuticals International 2005  Legal and Privacy Statement
Efudex® is a registered trademark of Valeant Pharmaceuticals International